WEKO3
アイテム
<Review> Target validation and drug discovery for in flammatory diseases
https://kindai.repo.nii.ac.jp/records/10536
https://kindai.repo.nii.ac.jp/records/105362d3655e0-9715-4940-9346-4a6030e59967
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AA0050842X-20111200-0045.pdf (1.5 MB)
|
|
| Item type | ☆紀要論文 / Departmental Bulletin Paper(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2012-02-02 | |||||||
| タイトル | ||||||||
| タイトル | <Review> Target validation and drug discovery for in flammatory diseases | |||||||
| 言語 | en | |||||||
| 著者 |
Takahashi, Hideo Kohka
× Takahashi, Hideo Kohka
|
|||||||
| 言語 | ||||||||
| 言語 | eng | |||||||
| キーワード | ||||||||
| 主題 | adhesion molecule, atherosclerosis, blood-brain barrier, high mobility group box-1, inflammatory diseases, interleukin-18, monocytes, neuron | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||
| 資源タイプ | departmental bulletin paper | |||||||
| 著者 所属 | ||||||||
| 値 | Department of Pharmacology, Kinki University, Faculty of Medicine | |||||||
| 著者所属(翻訳) | ||||||||
| 値 | 近畿大学医学部 | |||||||
| 版 | ||||||||
| 出版タイプ | VoR | |||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
| 出版者 名前 | ||||||||
| 出版者 | The Kinki University Medical Association | |||||||
| 書誌情報 |
en : ACTA MEDICA KINKI UNIVERSITY 巻 36, 号 2, p. 45-52, 発行日 2011-12-01 |
|||||||
| ISSN | ||||||||
| 収録物識別子タイプ | ISSN | |||||||
| 収録物識別子 | 03866092 | |||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | [Abstract] We have examined to find new factors, which are involved in inflammatory diseases including ischemic diseases. To investigate the mechanism of inflammation, we have proved that monocyte/macropharge plays roles in the up-stream of immune responses. Binding adhesion molecules on monocyte/macropharge and T-cell induces the activation of these cells. It is reported that monocyte/macropharge releases histamine, prostaglandin (PG)E2, interleukin (IL)-18 and high mobility group box-1 (HMGB1). We have found that these mediators regulate immune responses. Therefore, we suggested that histamine, IL-18 and HMGB1 are target for new treatment of inflammatory diseases. In the present review, I explain my findings as the followings. | |||||||
| フォーマット | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | application/pdf | |||||||
